Older AA/PNH patients who have myeloid driver mutations at baseline and a poor response to nontransplant treatment have a higher risk of progression to sMN. Baseline-prevalent mutations (PIGA/human ...
Iptacopan demonstrated significant hemoglobin improvements in PNH patients transitioning from anti-C5 therapies, validating its efficacy as an oral monotherapy. The safety profile of iptacopan was ...
In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results